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Reports
Tools to discriminate between targets of CK2 vs PLK2/
PLK3 acidophilic kinases
M. Salvi1, E. Trashi1, G. Cozza1, A. Negro, P.I. Hanson2, and L.A. Pinna1
1
Department of Biomedical Sciences, University of Padova, V.le G. Colombo 3, 35131 Padova, Italy, and
2
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA
While the great majority of Ser/Thr protein kinases are basophilic or proline directed, a tiny minority is acidophilic.
The most striking example of such “acidophilic” kinases is CK2, whose sites are specified by numerous acidic residues
surrounding the target one. However PLK2 and PLK3 kinases recognize an acidic consensus similar to CK2 when
tested on peptide libraries. Here we describe optimal buffer conditions for PLK2 and 3 kinase activity assays and
tools such as using GTP as a phosphate donor and the specific inhibitors CX-4945 and BI 2536, useful to discriminate between acidic phosphosites generated either by CK2 or by PLK2/PLK3.
Keywords: acidophilic kinase; CK2; PLK2; PLK3

Over the past few years, research in the field
of proteomics and phosphoproteomics has
witnessed a tremendous revolution allowing
for the highly confident characterization of
protein phosphorylation on a global scale.
Presently, more than 150,000 non-redundant phosphorylation sites have been
identified from ~18,000 proteins (www.
phosphosite.org). However, to date, the vast
majority of phosphorylation events are still
functionally uncharacterized and the link
between the phosphorylation site and the
kinases responsible is generally missing. In
a previous report, we suggested that major
contributions to the human phosphoproteome are provided by relatively few classes
of protein kinases, with special reference to
proline directed kinases, a few phosphate
directed kinases whose targeting is primed
by previously phosphorylated residues, and
by the highly acidophilic protein kinase
CK2 (1). In particular, we suggested that
this latter kinase might be responsible
alone for the generation of a substantial
proportion of the eukaryotic phosphoproteome (about 20%), based on its consensus
sequence, which shows distinctive features
not shared by any other kinases (2). The
minimum consensus sequence of CK2

requires an acidic residue in position +3
downstream from the phosphoacceptor site
(S/T-x-x-D/E/pS), and is generally accompanied by additional acidic residues (on
average more than 5), being also characterized by the absence of basic residues
in the proximity of the target aminoacid
(2–4). Considering that the continuously
growing repertoire of bona fide CK2
substrates already included more than 300
proteins in 2003 (4), CK2 could indeed
represent the most pleiotropic member of
the kinome.
Such a highly acidophilic consensus
sequence was considered an unique
signature of protein kinase CK2 until the
recent discovery that two members of the
Polo-like kinase (PLK) family, PLK2 and
PLK3 display a strong preference for acidic
residues at all positions between -4 and
+4 with respect to the target aminoacid
as judged from a peptide library assay (5).
Moreover, the very limited number of
bona fide PLK2 and PLK3 phosphosites
identified so far confirms their highly acidophilic nature (see www.phosphosite.org
for an updated list of identified phosphosites) (6). The preference of PLK2 and
PLK3 for acidic side chains surrounding

the phosphoacceptor residue discloses
the possibility that the consensus of these
kinases could at least partially overlap that
of protein kinase CK2. Indeed, as shown in
Table 1, the consensus sequence extracted
from peptide libraries for PLK2 and PLK3
is almost identical to the one calculated
by Songyang et al. (7) for CK2 using an
oriented peptide library. Accordingly, both
CK2 and PLK2/PLK3 are assayed using
the common artificial substrate casein.
These observations prompted us to
develop tools to discriminate between
phosphorylation performed by either CK2
or Polo-like acidophilic kinases.

Materials and methods

c-DNA constructs
Human PLK2-PGEX4TI (8), human
CK2α-PGEX4TI (9), and pcDNA3.1CHMP3 (10) were previously described.
For the preparation of the PLK3-PGEX4TI
plasmid, the human c-DNA encoding fulllength kinase inserted in pCMV6-XL4
vector was purchased from Origene
(NM_004073) and amplified by PCR using
primers to add BamhI and XhoI restriction
sites and inserted into the pGEX4T1 vector

Method summary:
Here we describe optimal buffer conditions for PLK2 and PLK3 kinase assays and approaches to discriminate between targets of PLK2/
PLK3 and CK2 acidophilic kinases, specifically the combined use of CX-4945 and BI 2536 as inhibitors in conjunction with GTP as
a phosphate donor.
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at BamhI and XhoI sites.
The CHMP3S200A mutant was
generated using the QuickChange-Site
directed Mutagenesis kit (Stratagene,
La Jolla, CA, USA) according to the
manufacturer’s instructions. Mutation was
confirmed by sequencing analysis.

Table 1. Position relative to phosphoacceptor residue.
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Overlapping of consensus sequences derived from peptide libraries for protein kinases PLK2, PLK3 and
CK2.

Inhibitors
BI 2536 was purchased from Selleck
Chemicals (Houston, TX, USA), CX-4945
was purchased from Synthesis Medchem
(Cambridge, UK), 4,5,6,7-tetrabromobenzotriazole (TBB) was synthesized
as described in Sarno et al. (11).

A

Expression and purification of
recombinant kinases
Expression and purification of GST-CK2α,
GST-PLK2, and GST-PLK3 was performed
as described in our earlier published work
(8).
In vitro phosphorylation
Reaction conditions for α-casein phosphorylation experiments were the following:
50 mM Tris/HCl, pH 7.5, 50 µM, (γ-33P)
ATP (specific radioactivity ~3000 cpm/
pmol), 1.5 µg α-casein, with the addition
of different amounts of MgCl2, NaCl, or
DTT (20 µl final volume). This amount
of casein corresponds to the apparent Km
of the phosphorylation reaction by PLK2
and PLK3 calculated in preliminary experiments (not shown). Experiments with
inhibitors were performed with 5 µM
(γ-33P)ATP (specific radioactivity ∼3000
cpm/pmol) in order to be at the Km for
ATP for the kinases (Km for ATP for
PLK2, PLK3, and CK2 is between 5–6
µM, as calculated in preliminary experiments not shown). The reaction was started
by the addition of protein kinases (50 ng
PLK2, 20 ng PLK3, 10 ng CK2). The
reaction mixtures were incubated for 10
min at 30°C and stopped by the addition
of Laemmli buffer and boiling followed
by SDS-PAGE and Coomassie staining.
Gels were dried and exposed overnight to
a multipurpose storage phosphor screen
and analyzed using a Cyclone storage
phosphor system (Perkin Elmer, Massachusetts, USA).
Cell culture, transfection, and
immunoprecipitation
293T cells were maintained in 5% CO2 in
DMEM supplemented with 10% FBS, 2
mM l-glutamine, 100 U/mL penicillin, and
100 mM streptomycin in an atmosphere
containing 5% CO2 . DNA Trasfection
was performed with Trans-IT (Mirus,
Madison, WI, USA) according to the
manufacturer’s instructions. Forty-eight

B

C

D

Figure 1. Characterization of PLK2 and PLK3 kinase activity on α-casein. (A-B) 1.5 µg of α-casein was
phosphorylated by PLK2 or PLK3 in a radioactive mixture (50 mM Tris, pH 7.5, 50 µM (γ-33P)ATP,
specific radioactivity ~3000 cpm/pmol) in the presence or absence of increasing concentrations of
Mg2+, Mn2+ (A) and NaCl (B) as indicated. Proteins were resolved by SDS/PAGE, Coomassie stained,
and analyzed by PhosphorImager. A representative picture of three independent experiments
is shown. On the right is reported the effect on α-casein activity of 5 and 10 mM Mn2+ as a
percentage of the activity measured with 10 mM Mg2+ (A) and NaCl effect as a percentage of the
activity measured in its absence (B) (mean values ± SD of three determinations are shown). (C)
Phosphorylation of α-casein by PLK2, PLK3, and CK2 in the presence of ATP or GTP. 1.5 µg of
α-casein was phosphorylated by PLK2, PLK3, or CK2 in 50 mM Tris (pH 7,5), 10 mM Mg2+, 50
µM (γ-33P)ATP (specific radioactivity ~3000 cpm/pmol) (lane 1), or 50 (lane 2) or 100 µM (lane
3) (γ-33P)GTP (with the same specific radioactivity) (mean values ± SD of three determinations
are shown). (D) 1.5 µg of α-casein was phosphorylated by PLK2 or PLK3 in a radioactive mixture
(50 mM Tris, pH 7.5, 10 mM Mg2+, 50 µM (γ-33P)ATP, specific radioactivity ~3000 cpm/pmol) in
the presence or absence of 1 mM DTT. Proteins were resolved by SDS/PAGE, Coomassie stained,
and analyzed by PhosphorImager. A representative picture of three independent experiments is
shown. On the right, the effect of DTT is quantified (mean values ± SD of three determinations
are shown).
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Figure 2. Effect of inhibitors on CK2 and PLK2/PLK3 kinase activity. Compared effect of TBB (A), CX4945 (B), and BI 2536 (C) on PLK2, PLK3, and CK2 activity. 2 µg of α-casein was phosphorylated
by PLK2, PLK3, or CK2 in the presence of increasing concentrations of inhibitor (mean values
± SD of three determinations are shown) in 50 mM Tris (pH 7.5), 10 mM Mg2+, 1mM DTT, 50
µM (γ-33P)ATP (specific radioactivity ~3000 cpm/pmol). IC50 for TBB were 0.35 µM (CK2), 0.65
µM (PLK3), 0.84 µM (PLK2). IC50 for CX-4945 are 0.03 µM (CK2), 0.88 µM (PLK3), 0.56 µM
(PLK2). IC50 for BI2536 are 0.08 µM (PLK3), 0.07 µM (PLK2) (not determined for CK2).

hours after transfection, cells were lysed
in 20 mM Tris–HCl (pH 8), 150 mM
NaCl, 2 mM EDTA, 2 mM EGTA, 1%
Triton X-100 (v/v), Complete Protease
Inhibitor Cocktail (Roche Diagnostics,
Indianapolis, Indiana, USA). Lysates were
incubated with monoclonal anti-cMyc
antibody (clone 9E10; Sigma), then with
30 µl of protein G-PLUS-Agarose (Santa
Cruz Biotechnology). Beads were washed
with PBS and incubated in the radioactive mixture consisting of 50 mM Tris
(pH 7.5), 10 mM Mg2+, and 50 µM ATP
((γ-33P)ATP ~3000 cpm/pmol) or 100 µM
GTP ((γ-33P)GTP ~3000 cpm/pmol), in
presence or absence of specific inhibitors.
The reaction was stopped with the addition
of 2 × Laemmli sample buffer, subjected to
SDS/PAGE, and blotted on PVDF. Blots
were exposed overnight to a multipurpose
storage phosphor screen and analyzed using
a Cyclone storage phosphor system (Perkin
Elmer).
In silico analysis
To analyze the molecular reasons for the
cross-selectivity between the inhibitors BI
2536 and CX4945, the crystal structure
complexes of BI 2536/PLK1 (PDB ID:
2RKU) and CX-4945/CK2 (PDB ID:
3PE1) were exploited. An in silico analysis
was carried out through molecular docking
experiments using MOE program (C. C.
G. Molecular Operating Environment

(MOE 2009.10), Inc., 1255 University St.,
Suite 1600, Montreal, Quebec, Canada,
H3B 3X3) and Schrödinger Glide (Glide,
version 5.5, Schrödinger, Inc., New York,
NY, 2009). Human PLK2/3 catalytic
subunits were built using an homology
modeling approach implemented into
MOE, using the PLK1 crystal structure
(2RKU) as a template. Hydrogen atoms
were added to the protein structure
using standard geometries with MOE; to
minimize contacts between hydrogens, the
structures were subjected to Amber99 force
field minimization until the root mean
square deviation of the conjugate gradient
was <0.1 kcal • mol−1 •Å−1 (1 kcal = 4.184
kJ; 1 Å = 0.1 nm), keeping the heavy atoms
fixed at their crystallographic positions. BI
2536 and CX4945 were rebuilt using MOE
builder and minimized using PM3 semiempirical quantum mechanics force field
implemented in Mopac 7. A set of docking
runs were performed using the program
Glide.

Results and discussion

We determined the optimal incubation
conditions and cofactor requirements for
PLK2 and PLK3 kinase activity. These
details have not previously been provided
for these two kinases, but the conditions
are well established for CK2 (12, 13). Here,
we used α-casein (Figure 1) as an artificial
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phosphorylatable substrate (equally suited
for testing CK2) and repeated the experiments with the physiological PLK2/PLK3
substrate, α-synuclein. We obtained comparable results from both substrates (Figure
S1). Figure 1A shows that both kinases
prefer Mg 2+ over Mn 2+, the latter being
almost ineffective with PLK3. In particular,
our results show that 2–10 mM Mn2+ could
be also used for PLK2 kinase assay (with
a reduction of efficiency of ~40%–50% if
compared with the activity obtained with
10 mM Mg2+). Conversely, PLK3 activity
obtained with all the Mn 2+ concentrations tested is always less than 10% of
that obtained with 10 mM Mg2+ (Figure
1A). NaCl exerts a dose-dependent inhibitory effect on both kinase activities, with
stronger effects on PLK3 activity (Figure
1B). The use of 10 mM Mg2+ without NaCl
is therefore suggested. This is the same as
commonly used for protein kinase CK2
(12, 13).
A peculiar characteristic of protein
kinase CK2 is its ability to use GTP as a
phosphodonor substrate almost as efficiently
as ATP (13). This property has been utilized
to highlight the CK2-dependent phosphoproteome in cellular lysates (14). In Figure
1C, we compared the ability of PLK2,
PLK3, and CK2 to use either ATP or
GTP in the phosphorylation reaction. As
expected, GTP can effectively replace ATP
for CK2 activity, but this was not the case
for PLK2 and PLK3. Therefore using GTP
allows discrimination between the activity
of CK2 and PLK2/PLK3 kinases. Figure
1D analyzes the possibility that PLK2
and PLK3 are redox-regulated enzymes:
the addition of the reducing agent DTT
shows a strong increase (up to six times) of
α-casein phosphorylation by both kinases
(Figure 1D). In silico analysis for cysteines
that potentially can form intra or intermolecular disulfide bridge and that are
conserved in both PLK2 and PLK3 kinases
disclosed two cysteines located in the ATP
binding cleft (Cys 96 and 162 for PLK2;
Cys 76 and 142 for PLK3) and one in the
activation loop (PLK2 Cys 241, PLK3
Cys 221) (Figure S2). Intriguingly these
cysteines are conserved also in PLK1 (Cys
67, Cys 133, and Cys 212), highlighting
the possibility that this group of kinases
presents a similar mechanism of redox
regulation.
Therefore, optimal buffer conditions for
both PLK2 and PLK3 kinases are 50 mM
Tris pH 7,5, 10 mM Mg2+, 1 mM DTT, and
no NaCl. This buffer is the same as utilized
for CK2, except for the presence of DTT
since the activity of this kinase is insensitive
to reducing agents (15).
Specific inhibitors could represent
www.BioTechniques.com/rd
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useful tools to discriminate between targets
affected by either CK2 or PLK2/PLK3.
Therefore CK2 inhibitor 4,5,6,7-tetrabromo-1H-benzotriazole (TBB) and the
recently developed CK2 inhibitor CX-4945,
which is in Phase I clinical trials for treating
cancer (16), and BI 2536, a potent inhibitor
of PLK kinases (17) were compared for
their ability to inhibit CK2, PLK2, and
PLK3. TBB is the most widely used CK2
inhibitor and its selectivity has been previously tested at 1 and 10 µM on a panel of 70
kinases which didn’t include PLK2/PLK3
kinases (18). Selectivity of CX-4945 has
been tested at a single concentration on a
panel of 235 kinases, including PLK2 and
PLK3, which were only slightly inhibited
(≤10% at 0,5 µM) (16). Figures 2A and
2B show the effect of TBB and CX-4945
on kinase activities. TBB was not useful
in discriminating between CK2 and PLK
since PLK2 and PLK3 were inhibited with
a similar IC50 (Figure 2A). In contrast
CX-4945 is almost ineffective on PLK2
and PLK3 up to 200 nM concentration
while CK2 at this concentration is totally
inhibited (Figure 2B). Figure 2C shows
the effects of PLK inhibitor BI 2536. The
selectivity of this compound against CK2
has never been tested. BI 2536 is absolutely
specific, giving clear-cut results: CK2 is fully
refractory to its inhibition up to concentrations of 10 µM (not shown), while
PLK2 and PLK3 activities are completely
suppressed by sub-micromolar concentrations of BI 2536. The structural basis for
the cross-selectivity between the two inhibitors could be explained by in silico analysis.
The binding mode of BI 2536 is conserved
both in PLK2 and PLK3; the sequence
similarity of the three polo-like kinases at
4.5Å from BI 2536 is about 80% and all
the residues interacting with BI 2536 are
conserved. On the other hand, the PLK and
CK2 ATP binding clefts are very different
(Figure 3A); the CK2 cavity is more hydrophobic and smaller, due to bulkier residues.
PLK2/3 present Ala 109/89, Leu 159/139,
Cys 96/76, Leu 88/68, Cys 162/142, while
in CK2 the corresponding residues are Val
66, Phe 113, Val 51, Leu 59, Val116. For this
reason, in the CK2 active site there is not
enough space to accommodate BI 2536; in
particular CK2 Val 66 and Val 53 fill up the
space for of BI 2536 7R-ethyl group, thus
preventing the binding of the inhibitor to
the hinge region.
On the other hand, the selective CK2
inhibitor CX-4945 binds to the PLK2/3
active site much less efficiently, since a point
mutation study on CK2 has revealed that
the inhibitor binding is largely dependent
on hydrophobic residues, notably V66 and
I174 (16), which are replaced in PLK2/3

B

A

Figure 3. Comparison between BI-2536 (A) and CX4945 (B) binding on PLK2/PLK3 and CK2. (A)
Comparison between BI 2536 binding on PLK2/PLK3 (upper), and on CK2 (lower). (B) Comparison
between CX4945 binding on PLK2/PLK3 (upper) and on CK2 (lower).

Figure 4. Discrimination between acidiphilic kinase activities. CHMP3-myc, immunoprecipitated
from HEK 293T cells, was incubated in the radioactive mixture (50 mM Tris pH 7.5, 10 mM
Mg2+, 50 µM (γ-33P)ATP, specific radioactivity ~3000 cpm/pmol). Lane 1: IP from cells transfected
with empty vector. Lane 2–5 IP from cells transfected with myc-CHMP3. Lane 1,2,4,5: standard
phosphorylation buffer (50 µM ATP33). Lane 3: 100 µM (γ-33P)GTP substituted for ATP (with
the same specific radioactivity). Lane 4: addition of 1 µM BI 2536. Lane 5 addition of 200 nM
CX-4945. Inset: phosphorylation of immunoprecipitated CHMP3-myc as above. Lane 1: IP from
cells transfected with empty vector. Lane 2 IP from cells transfected with myc-CHMP3. Lane 3 IP
from cells transfected with myc-CHMP3S200A. Samples were loaded on SDS/PAGE, subjected to
Western blot using anti-myc, and analyzed by PhosphorImager.

by smaller and less hydrophobic residues.
Moreover, PLK2/3 cannot host the stabilizing water molecule due to the presence
of Arg 165/145 instead of Asn 118 in CK2
(Figure 3B).

BioTechniques Rapid Dispatches doi: 10.2144/000113866

4

Collectively, these results indicate that
the combined use of CX-4945 and BI 2536
effectively discriminate between CK2 and
PLK2/PLK3.
To probe the reliability of this approach,
www.BioTechniques.com/rd
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we focused our attention on CHMP3, a
protein of the ESCRT-III complex that is
required for multivesicular body (MVB)
formation (19). CHMP3 phospho S200,
identified in different cell lines in large
scale mass spectrometry experiments
(see www.phosphosite.org for references), is adjacent to a very acidic cluster
(PPGAMA ApSEDEEEEE) and the
kinase responsible has not been identified.
As shown in Figure 4, CHMP3 immunoprecipitated from 293T cells is phosphorylated by a kinase that coimmunoprecipitates
with the protein. To gain information about
the kinase responsible for CHMP3 S200
phosphorylation, use of GTP (instead of
ATP) as a phosphate donor and inhibitors
BI 2536 and CX-4945 was exploited. The
results shown in Figure 4 show that GTP
is able to replace ATP in the phosphorylation reaction and that phosphorylation
is completely refractory to high concentrations of BI 2536, while potently inhibited by
a low concentration of CX-4945. Note that
phosphorylation of CHMP3 is completely
abrogated by the mutation of a phosphoacceptor residue (S200), which has been
shown to be phosphorylated in vivo (see
inset in Figure 4). Taken together, these
results provide a clear-cut demonstration
that the kinase that coimmunoprecipites
with and phosphorylates CHMP3 is CK2,
not PLK2/PLK3, suggesting that CK2 is
also the kinase responsible for CHMP3
phosphorylation in vivo.
In conclusion, the combined use of
CX-4945 and BI 2536, in conjunction
with GTP as phosphate donor, allows a neat
discrimination between acidic phosphosites generated either by CK2 or by PLK2/
PLK3.
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